# EDGAR Filing Document

**Accession Number:** 0001177648
**File Stem:** 0000000000-26-001607
**Filing Date:** 2026-2
**Character Count:** 2134
**Document Hash:** dd61e938a0aee08fc2e50999900d5469
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-001607.hdr.sgml**: 20260320

**ACCESSION NUMBER**: 0000000000-26-001607

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260217

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ENANTA PHARMACEUTICALS INC
- **CENTRAL INDEX KEY:** 0001177648
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 043205099
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-293390

**BUSINESS ADDRESS:**
- **STREET 1:** 4 KINGSBURY AVENUE
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** 617 607 0800

**MAIL ADDRESS:**
- **STREET 1:** 4 KINGSBURY AVENUE
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-26-046712

## Text-Extract

```

                                                           February 17, 2026

Jay R. Luly, Ph.D.
Chief Executive Officer
Enanta Pharmaceuticals Inc.
4 Kingsbury Avenue
Watertown, Massachusetts 02472

        Re: Enanta Pharmaceuticals Inc.
            Registration Statement on Form S-3
            Filed February 11, 2026
            File No. 333-293390
Dear Jay R. Luly, Ph.D.:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Jimmy McNamara at 202-551-7349 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Stacie Aarestad

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._